About Us

OUR COMPANY

ExoVectory is a biotechnology company developing exosomes as a next-generation delivery platform for gene therapeutics. Founded in 2020 as a spin-out from Erasmus MC, The Netherlands, we are headquartered at Leiden Bio Science Park and collaborate with world-leading academic and industry partners including LUMC, UMC Utrecht and Thermo Fisher Scientific. Since our founding, we have built a strong foundation, growing our team, protecting our intellectual property, generating proof-of-concept data, and securing over €3 million in non-dilutive funding.

ExoVectory company visual

Our mission is to transform exosomes into precision delivery vehicles for next-generation genetic therapies targeting life-threatening and currently untreatable diseases.

leadership team

Dr. Ir. Jeroen de Vrij

Dr. Ir. Jeroen de Vrij

CEO

Mr. Drs. Ernst Ligthart

Mr. Drs. Ernst Ligthart

Legal & Finance

Dr. Wouter W. Woud

Dr. Wouter W. Woud

Lead Technology Officer

Cees Juffermans

Cees Juffermans

Business Development

ADVISORS

Dr. Bram Bout

JJP Biologics

Vector technology, biologics development

Dr. Inez de Greef

Treeway

Drug development, biotech entrepreneurship

Dr. Audrey Sporrij

BioNTech

Biotech strategy, oncology

Prof. Mirjam Heemskerk

LUMC

Cell therapies, translational oncology

Dr. Koen Breyne

Harvard Medical School

Gene therapy, exosome applications